Additionally, it has been described that decreased GAB1 expression levels in head and neck cancer cell lines (HN4, HN6, HN12, HN13, and HN31) increased sensitivity to the EGFR inhibitor gefitinib by decreasing MAPK and AKT phosphorylation [51]. Here, GAB1 is linked to head and neck cancer.